Literature DB >> 1762471

A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention.

M Johannesson1, J Hedbrant, B Jönsson.   

Abstract

In this paper a computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention is presented. Cost-effectiveness analysis makes it possible to compare the cost-effectiveness of different interventions in order to maximize the health effects for a given amount of resources. The computer simulation model was written in Turbo-Pascal to be used on an IBM-PC-compatible. The model was based on the 8-year logistic multivariate risk equations for CHD and stroke from the Framingham Heart Study, but the regression coefficients can easily be changed if local data exist. The main advantages with the model are that it is easy to use, transparent, and flexible. The model was mainly developed for scientific purposes, but should be useful also for educational purposes and clinical decision analysis. The modelling approach used should also be useful in many other medical areas.

Entities:  

Mesh:

Year:  1991        PMID: 1762471     DOI: 10.3109/14639239109067657

Source DB:  PubMed          Journal:  Med Inform (Lond)        ISSN: 0307-7640


  11 in total

Review 1.  Selecting a decision model for economic evaluation: a case study and review.

Authors:  J Karnon; J Brown
Journal:  Health Care Manag Sci       Date:  1998-10

Review 2.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

Authors:  Fredrik Borgström; Olof Johnell; John A Kanis; Anders Oden; David Sykes; Bengt Jönsson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs.

Authors:  C Sanderson; M Kubin
Journal:  Health Care Manag Sci       Date:  2001-12

5.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 6.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

7.  Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics.

Authors:  M Johannesson; J Wikstrand; B Jönsson; G Berglund; J Tuomilehto
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

8.  The cost effectiveness of hypertension treatment in Sweden.

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

9.  Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.

Authors:  J A Kanis; F Borgström; O Johnell; A Oden; D Sykes; B Jönsson
Journal:  Osteoporos Int       Date:  2004-07-24       Impact factor: 4.507

10.  The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.

Authors:  N Zethraeus; O Ström; F Borgström; J A Kanis; B Jönsson
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.